Outcome variable | Follow-up sessions | Coefficeint (rESWTa VS LCsIb) | p value | 95% CI |
---|---|---|---|---|
á…Ÿ | ||||
Visual analogue scale | Baseline to week 1 | −0.10 | 0.90 | −1.7 to 1.5 |
Week 1 to week 4 | 0 .049 | 0.95 | − 1.6 to 1.7 | |
Week 4 to week 12 | −1.0 | 0.23 | −2.7 to 0.63 | |
Week 12 to week 24 | −1.2 | 0.17 | − 2.9 to 0.49 | |
Symptom severity score | Baseline to week 1 | 2.6 | 0.27 | −2.0 to 7.2 |
Week 1 to week 4 | 1.5 | 0.53 | −3.2 to 6.1 | |
Week 4 to week 12 | −1.9 | 0.43 | −6.5 to 2.8 | |
Week 12 to week 24 | −5.1 | 0.036* | −9.8 to −0.33 | |
Functional score | Baseline to week 1 | 0.43 | 0.81 | −3.1 to 3.9 |
Week 1 to week 4 | −0.20 | 0.91 | −3.7 to 3.3 | |
Week 4 to week 12 | −1.8 | 0.32 | −5.3 to 1.7 | |
Week 12 to week 24 | −4.5 | 0.015* | −8.1 to −0.87 | |
Boston questionnaire score | Baseline to week 1 | 3.0 | 0.43 | −4.5 to 11 |
Week 1 to week 4 | 1.3 | 0.74 | −6.2 to 8.8 | |
Week 4 to week 12 | −3.7 | 0.34 | −11 to 3.8 | |
Week 12 to week 24 | −9.5 | 0.015* | −17 to − 1.9 | |
Peak sensory distal latency | Baseline to week 12 | −0.24 | 0.022* | − 0.44 to − 0.034 |
SNAPc amplitude | Baseline to week 12 | −2.8 | 0.36 | −8.9 to 3.2 |
Motor distal latency | Baseline to week 12 | −0.038 | 0.84 | −0.41 to 0.33 |
CMAPd amplitude | Baseline to week 12 | −0.44 | 0.34 | −1.4 to 0.46 |